BASILIXIMAB AND ANTI-THYMOCYTE GLOBULIN AS AN INDUCTION OF IMMUNOSUPPRESSION IN RECIPIENTS OF VASCULARIZED ORGAN TRANSPLANTS
Abstract
Introduction and Aim: The advancement of immunosuppressive therapy has significantly increased organ transplantations. Among immunosuppressive agents, basiliximab and anti-thymocyte globulin (ATG) are key in induction therapy. However, clear guidelines on when to use basiliximab alone, ATG alone, or their combination are lacking, posing clinical challenges. This study aims to review recent data on basiliximab and ATG use in induction therapy post-transplant.
Materials and Methods: A literature review was conducted using PubMed with keywords “basiliximab”, “ATG” and “immunosupression" including articles published up to September 2024, focusing on studies from the last two years. The review targeted information on their application in induction immunosuppression after vascularized organ transplantation, effects relative to organ type, and drug combinations.
Results: Basiliximab and ATG differ in efficacy and side effects. ATG is more effective in reducing acute rejection, especially in high-risk patients, but carries higher infection and hematologic risks. Basiliximab has a better safety profile, suitable for elderly or low-risk patients. Treatment should be individualized by age, immunological risk, and infection susceptibility. Steroid continuation after basiliximab induction improves outcomes, a benefit not clearly seen with ATG.
Conclusion: Induction therapy is advised for high-risk patients and certain transplants, mainly using ATG, Grafalon, or basiliximab. ATG may be a safe, effective alternative to basiliximab, which is preferred in older or comorbid patients. Limited data support ATG use in other transplants like pediatric heart transplants. Further multicenter trials and personalized therapy are needed.
References
Statistical data on organ transplantation in Poland in 2024 provided by the Organizational and Coordination Center for Transplantation "Poltransplant" [accesed and cited 2025.06.01]. Available from: https://www.poltransplant.org.pl/statystyka_2024.html
Transplant Agents. (2020). In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases.
Torpey N, Bradley JA, Fung JJ. Immunosuppressive Therapy in Solid Organ Transplantation. In: Immunosuppressive Therapy in Solid Organ Transplantation. Springer, London; 2002:127-154. http://doi.org/10.1007/978-1-4471-0201-4_7
Hardinger, K. L., Brennan, D. C., & Klein, C. L. (2013). Selection of induction therapy in kidney transplantation. Transplant international : official journal of the European Society for Organ Transplantation, 26(7), 662–672. https://doi.org/10.1111/tri.12043
Mo, X. D., Hong, S. D., Zhao, Y. L., Jiang, E. L., Chen, J., Xu, Y., Sun, Z. M., Zhang, W. J., Liu, Q. F., Liu, D. H., Wan, D. M., Mo, W. J., Ren, H. Y., Yang, T., Huang, H., Zhang, X., Wang, X. N., Song, X. M., Gao, S. J., Wang, X., … Huang, X. J. (2022). Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis. American journal of hematology, 97(4), 458–469. https://doi.org/10.1002/ajh.26475
Acharya, S., Lama, S., & Kanigicherla, D. A. (2023). Anti-thymocyte globulin for treatment of T-cell-mediated allograft rejection. World journal of transplantation, 13(6), 299–308. https://doi.org/10.5500/wjt.v13.i6.299
Mohty M. (2007). Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia, 21(7), 1387–1394. https://doi.org/10.1038/sj.leu.2404683
Information about the mechanism of action of basiliximab from the producer's website. Creative Biolabs, Basiliximab Overwiew [accesed and cited 2025 06.01]. Available from: https://www.creativebiolabs.net/basiliximab-overview.htm
Hod, T., Levinger, S., Askenasy, E., Siman-Tov, M., Davidov, Y., Ghinea, R., Pencovich, N., Nachmani, I., & Mor, E. (2024). Basiliximab induction alone vs a dual ATG-basiliximab approach in first live-donor non-sensitized kidney transplant recipients with low HLA matching. Clinical kidney journal, 17(9), sfae236. https://doi.org/10.1093/ckj/sfae236
Dello Strologo A, Bartoli GA, Schifano E, Arena M, Salerno MP, Silvestri P, Citterio F, Romagnoli J, Grandaliano G. Low dose thymoglobulin-basiliximab induction protocol on incidence of acute rejection and posttransplant neoplasia: an observational retrospective study. Nephrol Dial Transplant 2023;38(Suppl_1):gfad063c_5509. http://doi.org/10.1093/ndt/gfad063c_5509
Gustavo Martinez-Mier, Pedro I. Moreno-Ley, Luis F. Budar-Fernández, Marco T. Méndez-López, Carlos A. Allende-Castellanos, Luis A. Jiménez-López, Daniel A. Barrera-Amoros, José Manuel Reyes-Ruiz, Low-Dose Thymoglobulin versus Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: Three-Year Follow-Up Study,Archives of Medical Research,Volume 55, Issue 6, 2024, 103047, ISSN 0188-4409, https://doi.org/10.1016/j.arcmed.2024.103047.
Nissaisorakarn, P., Patel, H., Cardarelli, F., & Amtul, A. (2024). A comparative analysis of kidney allograft outcomes in steroid use versus steroid discontinuation after basiliximab and ATG induction: A UNOS database study. Clinical nephrology, 102, 39–50. https://doi.org/10.5414/CN111033
Fulop, T., Larbi, A., Dupuis, G., Le Page, A., Frost, E. H., Cohen, A. A., Witkowski, J. M., & Franceschi, C. (2018). Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?. Frontiers in immunology, 8, 1960. https://doi.org/10.3389/fimmu.2017.01960
McGovern, K. E., Sonar, S. A., Watanabe, M., Coplen, C. P., Bradshaw, C. M., & Nikolich, J. Ž. (2023). The aging of the immune system and its implications for transplantation. GeroScience, 45(3), 1383–1400. https://doi.org/10.1007/s11357-022-00720-2
Kim, K. D., Lee, K. W., Park, J. B., Sim, W. S., Lim, M., Jeong, E. S., Kwon, J., & Yang, J. (2025). Necessity of induction agent modification for old age kidney transplant recipients. Kidney research and clinical practice, 44(2), 349–360. https://doi.org/10.23876/j.krcp.23.068
Kim, H. D., Bae, H., Yun, S., Lee, H., Eum, S. H., Yang, C. W., Oh, E.-J., & Chung, B. H. (2023). Impact of Induction Immunosuppressants on T Lymphocyte Subsets after Kidney Transplantation: A Prospective Observational Study with Focus on Anti-Thymocyte Globulin and Basiliximab Induction Therapies. International Journal of Molecular Sciences, 24(18), 14288. https://doi.org/10.3390/ijms241814288
Wang K, Xu X, Fan M. Induction therapy of basiliximab versus antithymocyte globulin in renal allograft: a systematic review and meta-analysis. Clin Exp Nephrol 2018;22(3):684-693. http://doi.org/10.1007/s10157-017-1480-z
Liu, Y., Zhou, P., Han, M., Xue, C. B., Hu, X. P., & Li, C. (2010). Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis. Transplantation proceedings, 42(5), 1667–1670. https://doi.org/10.1016/j.transproceed.2010.02.088
Masset, C., Kerleau, C., Blancho, G., Hourmant, M., Walencik, A., Ville, S., Kervella, D., Cantarovich, D., Houzet, A., Giral, M., Garandeau, C., Dantal, J., & Nantes DIVAT Consortium (2023). Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients. Transplant international : official journal of the European Society for Organ Transplantation, 36, 10816. https://doi.org/10.3389/ti.2023.10816
Ulrich, F., Niedzwiecki, S., Pascher, A., Kohler, S., Weiss, S., Fikatas, P., Schumacher, G., May, G., Reinke, P., Neuhaus, P., Tullius, S. G., & Pratschke, J. (2011). Long-term outcome of ATG vs. Basiliximab induction. European journal of clinical investigation, 41(9), 971–978. https://doi.org/10.1111/j.1365-2362.2011.02490.x
Hong, S. Y., Kim, Y. S., Jin, K., Han, S., Yang, C. W., Chung, B. H., & Park, W. Y. (2023). The comparative efficacy and safety of basiliximab and antithymocyte globulin in deceased donor kidney transplantation: a multicenter cohort study. Kidney research and clinical practice, 42(1), 138–148. https://doi.org/10.23876/j.krcp.21.159
Zang S, Zhang X, Niu J, Das BB. Impact of induction therapy on cytomegalovirus infection and post-transplant outcomes in pediatric heart transplant recipients receiving routine antiviral prophylaxis. Clin Transplant. 2023 Jan;37(1):e14836. doi: 10.1111/ctr.14836. Epub 2022 Nov 9. PMID: 36259556.
Durlik M, Danielewicz R, et al. Recommendations for Immunosuppressive Therapy After Vascularized Organ Transplantation, Polish Transplantation Society, Warsaw, December 2021. ISBN: 978-83-921809-3-7.
Views:
6
Downloads:
1
Copyright (c) 2025 Marcin Sawczuk, Aleksandra Gradek, Dominika Nowak, Adam Zarzycki, Julia Tarnowska, Filip Szydzik, Bartosz Żegleń, Katarzyna Kozon, Monika Grudzień, Patryk Macuk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
